Trial Profile
A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2021
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Lacnotuzumab (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 08 Dec 2021 Planned primary completion date changed from 30 Sep 2021 to 30 Sep 2024.
- 13 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 02 Aug 2018 Status changed from not yet recruiting to recruiting.